Akero Therapeutics, Inc. (AKRO): Price and Financial Metrics

Akero Therapeutics, Inc. (AKRO): $27.81

0.82 (+3.04%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add AKRO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#356 of 360

in industry

AKRO Price/Volume Stats

Current price $27.81 52-week high $58.38
Prev. close $26.99 52-week low $11.25
Day low $27.07 Volume 2,718,100
Day high $30.47 Avg. volume 1,040,476
50-day MA $22.58 Dividend yield N/A
200-day MA $33.41 Market Cap 1.55B

AKRO Stock Price Chart Interactive Chart >


Akero Therapeutics, Inc. (AKRO) Company Bio


Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.


AKRO Latest News Stream


Event/Time News Detail
Loading, please wait...

AKRO Latest Social Stream


Loading social stream, please wait...

View Full AKRO Social Stream

Latest AKRO News From Around the Web

Below are the latest news stories about AKERO THERAPEUTICS INC that investors may wish to consider to help them evaluate AKRO as an investment opportunity.

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review Phase 3 Study and Regulatory Path for Treatment of NASH/MASH Patients with Compensated Cirrhosis (F4) SOUTH SAN FRANCISCO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious me

Yahoo | December 18, 2023

Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ...

In a notable insider trading event, President and CEO Andrew Cheng of Akero Therapeutics Inc (NASDAQ:AKRO) sold 26,978 shares of the company on December 11, 2023.

Yahoo | December 13, 2023

12 Most Promising Stocks to Buy According to Hedge Funds

In this article, we will take a look at the 12 most promising stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Promising Stocks to Buy According to Hedge Funds. Analysts and financial institutions are starting to release their 2024 market outlook reports and predictions and you […]

Yahoo | December 5, 2023

Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results

Advances in NASH Treatment Candidate Efruxifermin (EFX) with Phase 3 Trials on the Horizon

Yahoo | November 15, 2023

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates. “We continue to be encouraged b

Yahoo | November 13, 2023

Read More 'AKRO' Stories Here

AKRO Price Returns

1-mo 32.55%
3-mo 57.47%
6-mo N/A
1-year -41.55%
3-year -13.07%
5-year N/A
YTD 19.10%
2023 -57.39%
2022 159.10%
2021 -18.02%
2020 16.24%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!